Appendix M. 
385 
Kocher AA, Schuster MD, Szabolcs MJ. Takuma S. Burkhoff D. Wang J. 
Homma S, Edwards NM, Itescu S. Neovascularization of ischemic 
myocardium by human bone-marrow-derived angioblasts prevents 
cardiomyocyte apoptosis, reduces remodeling and improves cardiac 
function. Nature Med. 2001; 7; 430-6. 
Asahara T, Takahashi T, Masuda H, Kalka C. Chen D. Iwaguro H. Inai Y. 
Silver M, Isner JM. VEGF contributes to postnatal neovascularization by 
mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 
18:3964-3972. 
Kocher A, Schuster M, Szabolcs M, Itescu S. Cardiomyocyte regeneration 
after neovascularization of ischemic myocardium by h uman bone marrow- 
derived angioblasts. Nature Medicine 2002, in press. 
McEwan PE, Gray GA. Sherry L, Webb DJ, Kenyon CJ. Di^rential effects of 
angiotensin II on cardiac cell proliferation and intramyocardial perivascular 
fibrosis in vivo. Circulation 1998:98:2765-2773. 
Kawano H. Do YS, Kawano Y, Starnes V, Barr M, Law RE, Hsueh WA. 
Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. 
Circulation 2000;101:1130-1137. 
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and 
morbidity in patients with left ventricular dysfunction after myocardial 
infarction. Results of the survival and ventricular enlargement trial. The 
SAVE investigators. N Engl J Med 1992;327:669-677. 
Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus 
captopril in patients over 65 with heart failure (Evaluation of Losartan in the 
Elderly Study, ELITE). Lancet 1997;349:747-752. 
PRE -PUBLICATION VERSION 
